

# TGX-221

Catalog No: tcsc0110



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

663619-89-4

**Formula:**

$C_{21}H_{24}N_4O_2$

**Pathway:**

PI3K/Akt/mTOR

**Target:**

PI3K

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

364.44

## Product Description


TGX-221 is a potent, selective, and cell membrane permeable inhibitor of the **PI3K p110β** catalytic subunit, used for cancer

treatment.

IC50 & Target: IC50: 8.5 nM (p110 $\beta$ ), 211 nM (p110 $\delta$ )<sup>[5]</sup>

**In Vitro:** TGX-221, BL05 and BL05-HA show selective cytotoxicity to LNCaP cells, which may be due to the deficiency of PTEN in this cell line and the accumulation of PIP3 in the cells<sup>[1]</sup>. TGX-221 (1  $\mu$ M) does not affect the expression and phosphorylation of AMPK in C2C12 myoblasts<sup>[2]</sup>. TGX221 (0.1, 1, 10  $\mu$ M) induces IL-6 release from ASM cells<sup>[2]</sup>. TGX-221 does not affect neurotensin-stimulated Akt phosphorylation when used alone, but it further suppresses neurotensin-stimulated phosphorylation of Akt when combined with gefitinib. TGX-221 abolishes the neurotensin-stimulated phosphorylation of Akt in Panc-1 cells<sup>[3]</sup>.

**In Vivo:** TGX-221 (TGX221, 2.5 mg/kg i.v.) abolishes cyclic flow reductions in a Folts-like carotid artery stenosis preparation of thrombosis, without changing bleeding time, heart rate, blood pressure or carotid vascular conductance<sup>[4]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!